infectious diseases
Rifamycins
Rifaximin
Rifaximinis a derivative ofrifamycinthat is poorly absorbed after oral administration; 97% is recovered primarily unchanged in feces. Rifaximincan be used for empiric treatment of Traveler’s diarrhea , which is caused primarily by enterotoxigenic and enteroaggregative Rifaximinis not known to be effective for diarrhea due to enteric pathogens other thanE. coli. Becauserifaximinis not systemically absorbed, it should not be used to treat infectious diarrhea caused by invasive enteric bacterial pathogens (eg,Shigellaspecies,Salmonellaspecies,Campylobacterspecies). The dose for traveler's diarrhea is 200 mg orally every 8 hours for 3 days in adults and children>12 years. Rifaximinmay also be used for the treatment of Portosystemic Encephalopathy : The dosage is 550 mg orally 2 times a day. Irritable Bowel Syndrome (IBS) (IBS): The dosage is 550 mg orally 3 times a day. Adverse effects ofrifaximininclude nausea, vomiting, abdominal pain, and flatulence. 